Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasion

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Bernier, Ashlyn J ^a   Zhang, Jing ^a   Lillehoj, Erik ^b   Shaw, Andrew R E ^a   Gunasekara, Nirosha ^a   Hugh, Judith C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DIMER; INTERCELLULAR ADHESION MOLECULE 1; MUCIN 1; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CALCIUM SIGNALING; CELL INVASION; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ONCOGENE SRC; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; WILD TYPE; BIOLOGICAL MODEL; BREAST TUMOR; CANCER INVASION; CARCINOMA; CELL STRAIN HEK293; CHEMISTRY; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CYSTEINE; FEMALE; HEK293 CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MODELS, BIOLOGICAL; MUCIN-1; NEOPLASM INVASIVENESS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RNA, SMALL INTERFERING; SRC-FAMILY KINASES;

EID: 79960654379     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-93     Document Type: Article

References (49)

1. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-76. 10.1200/JCO.2008.18.1024, 2667821, 19204205.
2. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer 2006, 5:57. 10.1186/1476-4598-5-57, 1636664, 17083744.
3. Pitroda SP, Khodarev NN, Beckett MA, Kufe D, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009, 106:5837-41. 10.1073/pnas.0812029106, 2656554, 19289846.
4. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996, 56:4244-9.
5. Rahn JJ, Shen Q, Mah BK, Hugh JC. MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J Biol Chem 2004, 279:29386-90. 10.1074/jbc.C400010200, 15169768.
6. Shen Q, Rahn JJ, Zhang J, Gunasekera N, Sun X, Shaw A, Hendzel MJ, Hoffman P, Bernier A, Hugh JC. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res 2008, 6:555-67. 10.1158/1541-7786.MCR-07-2033, 18403635.
7. Rahn JJ, Chow JW, Horne GJ, Mah B, Emerman J, Hoffman P, Hugh JC. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005, 22:475-83. 10.1007/s10585-005-3098-x, 16320110.
8. Rahn J, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001, 91:1973-82. 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A, 11391575.
9. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 1995, 233(2):607-17. 10.1111/j.1432-1033.1995.607_2.x, 7588808.
10. Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH. The MUC1 SEA module is a self-cleaving domain. J Biol Chem 2005, 280:33374-86. 10.1074/jbc.M506047200, 15987679.
11. Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 2006, 13:71-6. 10.1038/nsmb1035, 16369486.
12. Carson DD. The cytoplasmic tail of MUC1: a very busy place. Sci Signal 2008, 1:35.
13. Yang N, Wang X, Jiang J, Frank SJ. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol 2007, 12(9):814-21.
14. Thelen M, Muñoz LM, Rodríguez-Frade JM, Mellado M. Chemokine receptor oligomerization: functional considerations. Curr Opin Phamacol 2010, 1:38-43.
15. Zhang Y, Jiang J, Kopchick JJ, Frank SJ. Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J Biol Chem 1999, 274:33072-84. 10.1074/jbc.274.46.33072, 10551877.
16. Goldsmith JF, Lee SJ, Jiang J, Frank SJ. Growth hormone induces detergent insolubility of GH receptors in IM-9 cells. Am J Physiol 1997, 273:932-41.
17. Zhang Y, Guan R, Jiang J, Frank SJ. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J Biol Chem 2001, 276:24565-73. 10.1074/jbc.M101281200, 11309389.
18. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, Kufe D. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007, 282:19321-30. 10.1074/jbc.M703222200, 17500061.
19. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009, 69:5133-41. 2721222, 19491255.
20. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A. MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol 2006, 21(8):849-55.
21. Meerzaman D, Xing PX, Kim KC. Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin. Am J Physiol Lung Cell Mol Physiol 2001, 278(3):625-9.
22. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004, 279(44):45721-7. 10.1074/jbc.M408027200, 15322085.
23. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003, 278(37):35458-64. 10.1074/jbc.M301987200, 12826677.
24. Whitney ML, Otto KG, Blau CA, Reinecke H, Murry CE. Control of myoblast proliferation with a synthetic ligand. J Biol Chem 2001, 276(44):41191-6. 10.1074/jbc.M103191200, 11502737.
25. Song GJ, Hinkle PM. Regulated dimerization of the thyrotropin-releasing hormone receptor affects receptor trafficking but not signaling. Mol Endocrinol 2005, 19(11):2859-70. 10.1210/me.2005-0133, 16020481.
26. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989, 44:265-311.
27. Boirsier JP, Alcover A, Herve F, Laisney I, Acuto O. Evidence for an extended structure of the T-cell coreceptor CD8α as deduced from the hydrodynamic properties of soluble forms of the extracellular region. J Biol Chem 1993, 268:2013-2020.
28. Al Masri A, Gendler SJ. Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene 2005, 24(38):5799-808. 10.1038/sj.onc.1208738, 15897873.
29. Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 2009, 35(2):337-45.
30. Ogawa M, Umehara K, Yu W, Uekusa Y, Nakajima C, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T. A Critical Role for a Peritumoral Stromal Reaction in the Induction of T-Cell Migration Responsible for Interleukin A -12-induced Tumor Regression. Cancer Res 1999, 59:1531-1538.
31. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996, 74(1):13-33. 10.1007/BF00202069, 8834767.
32. Shalloway D, Coussens PM, Yaciuk P. Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells. Proc Natl Acad Sci USA 1984, 81:7071-5. 10.1073/pnas.81.22.7071, 392078, 6594680.
33. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006, 13:53-9.
34. Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martín-Pérez J. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006, 281:20851-64. 10.1074/jbc.M601570200, 16728403.
35. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006, 97:263-74. 10.1007/s10549-005-9120-9, 16333527.
36. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007, 67:1580-8. 10.1158/0008-5472.CAN-06-2027, 17308097.
37. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor K, Green TP, Nicholson RI. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009, 115:57-67. 10.1007/s10549-008-0058-6, 18493848.
38. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008, 7:1185-94. 10.1158/1535-7163.MCT-08-0126, 2794837, 18483306.
39. Hanson JM, BroweIl DA, Cunliffe WJ, Varma J, Allen A, Hemming D, Shenton BK, Young JR, Higgs MJ, Brotherick I, Pearson JP. MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res Treat 2001, 67:215-22. 10.1023/A:1017955726902, 11561767.
40. Paszkiewicz-Gadek A, Porowska H, Anchim T, Wolczski S, Gindzienski A. Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen. Gynecol Endocrinol 2003, 17:37-44.
41. Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochemical and Biophysical Research Communications 2007, 362(3):740-6. 10.1016/j.bbrc.2007.08.074, 17764657.
42. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001, 8:269-80. 10.1016/S1097-2765(01)00304-5, 11545730.
43. Mahanta S, Fessler SP, Park J, Bamdad C. A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One 2008, 3(4):2054.
44. Leichert LI, Linke K. Protein thiol modifications visualized in vivo. PLoS Biol 2004, 2(11):333.
45. Linke K, Jakob U. Not every disulfide lasts forever: disulfide bond formation as a redox switch. Antiox and Redox Signal 2003, 5(4):425-434.
46. Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Update 2009, 12(3):65-73.
47. Bristol-Myers Squib Synopsis: Final Clinical Study Report for CA180003. 2007, Bristol-Myers Squib., http://ctr.bms.com/pdf/CA180003.pdf
48. Schenone S, Brullo C, Musumeci F, Botta M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs 2010, 19(8):931-45. 10.1517/13543784.2010.499898, 20557276.
49. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010, 107(15):6994-9. 10.1073/pnas.0912708107, 2872436, 20335537.